Skip to main content
. 2016 May 11;107(6):755–763. doi: 10.1111/cas.12932

Figure 5.

Figure 5

Maximum shrinkage of solid tumors and estrogen receptor‐positive, human epidermal growth factor receptor 2‐negative advanced breast cancer tumors treated with palbociclib 100 or 125 mg once daily and palbociclib 125 mg combined with letrozole (LET). Tumors were assessed using Response Evaluation Criteria in Solid Tumors version 1.1. Palbociclib 125 mg + LET. Palbociclib 100 mg.